TGA reminder on tocilizumab and hepatotoxicity

The TGA has issued a reminder to rheumatologists to be vigilant for liver adverse events with tocilizumab. In its latest Medicines Safety Update, the regulator says a recent review of Australian adverse events reports identified eight cases of tocilizumab-related moderate to severe drug-induced liver injury, including acute liver failure, hepatitis and jaundice. The liver adverse ...

Already a member?

Login to keep reading.

© 2021 the limbic